LifeMD, Inc. (LFMD)
| Market Cap | 114.24M -57.2% |
| Revenue (ttm) | 191.59M +20.8% |
| Net Income | -2.91M |
| EPS | -0.09 |
| Shares Out | 48.20M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 920,650 |
| Open | 2.300 |
| Previous Close | 2.290 |
| Day's Range | 2.220 - 2.380 |
| 52-Week Range | 2.060 - 5.550 |
| Beta | 2.17 |
| Analysts | Strong Buy |
| Price Target | 8.13 (+242.83%) |
| Earnings Date | Nov 9, 2026 |
About LFMD
LifeMD, Inc. operates as a direct-to-patient telehealth company, engages in the provision of patients access to virtual medical care and pharmacy services in the United States. It offers telehealth platform comprising Rex MD, a men’s telehealth platform that provides virtual diagnosis, treatment, and prescription medications for men’s health conditions, including erectile dysfunction, premature ejaculation, hair loss, insomnia, weight loss, and performance anxiety; and ShapiroMD that provides virtual medical treatment, prescription medications,... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for LFMD stock is "Strong Buy." The 12-month stock price target is $8.13, which is an increase of 242.83% from the latest price.
News
LifeMD Reschedules Third Quarter 2026 Earnings Release and Conference Call to November 12, 2026
NEW YORK, Nov. 06, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today announced that the Company has rescheduled its third qu...
LifeMD expands access to Eli Lilly self-pay GLP-1 medicines
LifeMD (LFMD) announced an arrangement with Eli Lilly (LLY) that enables LifeMD’s affiliated pharmacy to directly dispense and ship Lilly’s self-pay GLP-1 medicines, including Zepbound and Foundayo, t...
LifeMD expands access to Lilly's self-pay GLP-1 medicines, enabling option to dispense and ship directly to patients nationwide
Eligible patients prescribed Zepbound® or Foundayo® through LifeMD can now receive authentic Lilly medicines at Lilly's self-pay prices through LifeMD's affiliated pharmacy Eligible patients prescribe...
LifeMD to Report Third Quarter 2026 Financial Results on November 9
NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, announces that it will report financial results for the three...
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today announced that its Board of Directors has authorized a...
Wainwright says LifeMD-AT&T partnership creates mutually beneficial opportunity
Commenting on LifeMD’s (LFMD) exclusive collaboration with AT&T (T), which allows eligible AT&T wireless and fiber customers to receive a complimentary LifeMD membership with on-demand access to a nat...
AT&T announces collaboration with LifeMD, customers to receive membership
AT&T (T) announced that more than 100 million eligible wireless and fiber customers will receive complimentary access to LifeMD’s (LFMD) virtual care and pharmacy platform. “AT&T is delivering more va...
AT&T Becomes the First and Only Carrier to Offer Free Access to Virtual Healthcare Powered by LifeMD
DALLAS, Sept. 15, 2026 /PRNewswire/ -- Through an exclusive collaboration with LifeMD, eligible AT&T wireless and fiber customers receive a complimentary LifeMD membership, a $228 annual value, with o...
LifeMD transferred with Buy rating at B. Riley
B. Riley kept a Buy rating on LifeMD (LFMD) with an $8 price target following a transfer of coverage. The company has a branded-therapy orientation versus a compounding-heavy model, which…
LifeMD price target lowered to $5 from $8 at KeyBanc
KeyBanc analyst Scott Schoenhaus lowered the firm’s price target on LifeMD (LFMD) to $5 from $8 and keeps an Overweight rating on the shares.
LifeMD price target lowered to $9 from $10 at H.C. Wainwright
H.C. Wainwright analyst Yi Chen lowered the firm’s price target on LifeMD (LFMD) to $9 from $10 and keeps a Buy rating on the shares. The company reported a sales…
LifeMD price target lowered to $8 from $10 at B. Riley
B. Riley analyst Anderson Schock lowered the firm’s price target on LifeMD (LFMD) to $8 from $10 and keeps a Buy rating on the shares following the company’s Q2 report…
LifeMD price target lowered to $5 from $8 at Lake Street
Lake Street lowered the firm’s price target on LifeMD (LFMD) to $5 from $8 and keeps a Buy rating on the shares after the company reported “soft” Q2 results and…
LifeMD price target lowered to $7 from $8 at Mizuho
Mizuho lowered the firm’s price target on LifeMD (LFMD) to $7 from $8 and keeps an Outperform rating on the shares.
LifeMD price target lowered to $9 from $10 at BTIG
BTIG lowered the firm’s price target on LifeMD (LFMD) to $9 from $10 and keeps a Buy rating on the shares. LifeMD reported a weaker-than-expected Q2 with lower revenue and…
UPDATE - LifeMD Reports Second Quarter 2026 Results
UPDATE this press release has been updated to remove a duplicate table. Second quarter 2026 revenue of $47.3 million, within the Company's guidance range of $47 million to $50 million; adjusted EBITDA...
LifeMD sees Q3 revenue $48M-$51M, consensus $58.55M
Sees Q3 adjusted EBITDA loss of $1M to gain of $2M. “This transition to branded GLP-1 medications has weighed on near-term profitability, but it has produced a fundamentally stronger company…
LifeMD cuts FY26 revenue view to $205.5M-$212.5M from $220M-$230M
Consensus $222.05M. Cuts FY26 revenue view to loss of $6B to break even from $12M-$17M. “The second quarter reflected the planned step-down in marketing investment we described on our last…
LifeMD reports Q2 EPS (16c), consensus (5c)
Reports Q2 revenue $47.3M, consensus $49.1M. “Revenue of $47.3 million came in within our guidance range, and while adjusted EBITDA finished below the range we guided to, it improved approximately…
LifeMD Earnings Call Transcript: Q2 2026
Q2 revenue was $47.3M, with gross margin expanding to 89% and recurring bill revenue at 84%. Strategic shifts to branded therapies, longer memberships, and diversified acquisition channels led to a revised 2026 outlook, but profitability is expected to improve in H2.
LifeMD Earnings release: Q2 2026
LifeMD released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
LifeMD Slides: Q2 2026
LifeMD has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
LifeMD Quarterly report: Q2 2026
LifeMD has published its Q2 2026 quarterly earnings report on August 5, 2026.
LifeMD to Report Second Quarter 2026 Financial Results on August 5
NEW YORK, July 24, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and six mont...
LifeMD partners with Halozyme subsidiary for exclusive testosterone program
LifeMD (LFMD) announced a strategic co-marketing collaboration with Antares Pharma, a subsidiary of Halozyme (HALO), supporting a direct-to-patient self-pay program for Xyosted. Under the agreement, L...